About: http://data.cimple.eu/news-article/3c7a20708930e4c2c53751259d845119a1b5fe09558e9be85ad58a2b

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/3c7a20708930e4c2c53751259d845119a1b5fe09558e9be85ad58a2b Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US biotech company Novavax said Monday it hopes to file for British approval of its Covid-19 vaccine at the start of the second quarter of 2021, and to do the same soon after in the United States. The company has no assurance that US authorities will agree to consider the request, which currently is based on results from Phase 3 clinical trials led in the Britain. Similar trials are still ongoing in the United States. The data will hopefully be presented to the British health regulator (MHRA) "by early second quarter 2021," Novavax said in a statement, on the occasion of the publication of its quarterly results. There is an "ongoing dialogue" with the US Food and Drug Administration (FDA), "with potential for EUA (emergency use authorization) filing in the second quarter of 2021," the statement said. "Our hope and expectation is that the FDA will agree to review the UK data as part of the EUA filing in the US," Novavax CEO Stanley Erck told CBS, though he acknowledged there was no assurance that the FDA will do so. Erck added that Novavax has "a different dataset than AstraZeneca," which developed a vaccine with Oxford University. US health authorities are waiting for the results of trials led in the United States before approving the AstraZeneca jab, even though the drug is already approved in Europe. If the FDA refuses to study Novavax's British data, the approval procedure will be postponed until the results of its trials in the United States and Mexico, for which 30,000 volunteers have been inoculated, are known. That will likely be in the second quarter of 2021, depending on the virulence of the Covid-19 epidemic in the two countries, according to the Novavax statement. The clinical trials conducted in Britain involved 15,000 people and showed 89.3 percent efficacy for the vaccine, Novavax announced at the end of January. The Novavax vaccine was 95.6 percent effective against the original Covid-19 strain and 85.6 percent effective against the British variant. The British government has secured an order for 60 million doses of the Novavax jab. la/to/jh
schema:headline	Novavax hopes to file for US vaccine approval in 2nd quarter of 2021
schema:mentions	Novavax Virulence Medicines and Healthcare products Regulatory Agency USA Gymnastics CBS Jab University of Oxford AstraZeneca Food and Drug Administration Chief executive officer Mexico European Union United Kingdom Vaccine United States Coronavirus disease 2019
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-01 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	70 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software